CD274 and neoplasm: Previous researches have suggested that AGC patients with high programmed cell death ligand-1 (PD-L1) expression, microsatellite instability-high (MSI-H) status, and high tumor mutational burden (TMB) may be a population that benefits from immune checkpoint inhibitors (ICIs) therapy 4,6,7.